Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;48(7):2225-2232.
doi: 10.1007/s00259-021-05191-9. Epub 2021 Jan 26.

Relationship between amyloid and tau levels and its impact on tau spreading

Affiliations

Relationship between amyloid and tau levels and its impact on tau spreading

Vincent Doré et al. Eur J Nucl Med Mol Imaging. 2021 Jul.

Abstract

Purpose: Previous studies have shown that Aβ-amyloid (Aβ) likely promotes tau to spread beyond the medial temporal lobe. However, the Aβ levels necessary for tau to spread in the neocortex is still unclear.

Methods: Four hundred sixty-six participants underwent tau imaging with [18F]MK6420 and Aβ imaging with [18F]NAV4694. Aβ scans were quantified on the Centiloid (CL) scale with a cut-off of 25 CL for abnormal levels of Aβ (A+). Tau scans were quantified in three regions of interest (ROI) (mesial temporal (Me); temporoparietal neocortex (Te); and rest of neocortex (R)) and four mesial temporal region (entorhinal cortex, amygdala, hippocampus, and parahippocampus). Regional tau thresholds were established as the 95%ile of the cognitively unimpaired A- subjects. The prevalence of abnormal tau levels (T+) along the Centiloid continuum was determined.

Results: The plots of prevalence of T+ show earlier and greater increase along the Centiloid continuum in the medial temporal area compared to neocortex. Prevalence of T+ was low but associated with Aβ level between 10 and 40 CL reaching 23% in Me, 15% in Te, and 11% in R. Between 40 and 70 CL, the prevalence of T+ subjects per CL increased fourfold faster and at 70 CL was 64% in Me, 51% in Te, and 37% in R. In cognitively unimpaired, there were no T+ in R below 50 CL. The highest prevalence of T+ were found in the entorhinal cortex, reaching 40% at 40 CL and 80% at 60 CL.

Conclusion: Outside the entorhinal cortex, abnormal levels of cortical tau on PET are rarely found with Aβ below 40 CL. Above 40 CL prevalence of T+ accelerates in all areas. Moderate Aβ levels are required before abnormal neocortical tau becomes detectable.

Keywords: Alzheimer’s disease; Aβ-amyloid imaging; Neurodegeneration; Positron emission tomography; Tau imaging; Tauopathies.

PubMed Disclaimer

Conflict of interest statement

Christopher C. Rowe has received research grants from NHMRC, Enigma Australia, Biogen, Eisai, and Abbvie. He is on the scientific advisory board for Cerveau Technologies and Biogen Australia. Victor Villemagne is and has been a consultant or paid speaker at sponsored conference sessions for Eli Lilly, Life Molecular Imaging, GE Healthcare, Abbvie, Lundbeck, Shanghai Green Valley Pharmaceutical Co. Ltd., and Hoffmann La Roche. All the other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Representative axial, coronal, and sagittal Aβ and tau PET images across the spectrum of Centiloid values
Fig. 2
Fig. 2
Histograms and stacked plot of the percentage of tau-positive subjects among the whole population versus Centiloid scores. Cognitive groups are colour-coded (CU: blue, MCI: green, AD: red)
Fig. 3
Fig. 3
Prevalence (percentage) of high-tau (T+) CU subjects among the cognitively unimpaired subjects
Fig. 4
Fig. 4
Scatter plot of Centiloid versus the log tau SUVR in the Me (left) and Te (middle) and R (right) ROI in 3 different colour-coded clinical diagnostic groups, with light colours used to identify A- subjects. Thresholds are displayed in fine dash vertical and horizontal lines. Peri-thresholds are in grey shadow and a sigmoid curve has been fitted to the whole population. The thick dash horizontal line shows the CL value at which tau SUVR reaches the threshold for elevated tau.
Fig. 5
Fig. 5
Scatter plot of tau SUVR in the Me (left) and Te (middle) and R (right) ROI versus age at tau scan in 2 different colour-coded clinical diagnostic groups (cognitively unimpaired (CU) and cognitively impaired (CI)), with light colours used to identify A- subjects

References

    1. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–357. doi: 10.1016/S0197-4580(97)00056-0. - DOI - PubMed
    1. Delacourte A, David JP, Sergeant N, Buée L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology. 1999;52:1158–1165. doi: 10.1212/wnl.52.6.1158. - DOI - PubMed
    1. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–1800. doi: 10.1212/wnl.58.12.1791. - DOI - PubMed
    1. Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14:225–236. doi: 10.1038/nrneurol.2018.9. - DOI - PubMed
    1. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319. doi: 10.1002/ana.20009. - DOI - PubMed

Publication types